ALKERMES reported $201.73M in Gross Profit on Sales for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Gross Profit On Sales Change
Acadia Pharmaceuticals ACAD:US USD 128.58M 3.32M
Amgen AMGN:US USD 5.06B 20M
Biogen BIIB:US USD 2.04B 66.1M
Biomarin Pharmaceutical BMRN:US USD 389.06M 21.62M
Bluebird Bio BLUE:US USD 71K 297K
Bristol Myers Squibb BMY:US USD 8.86B 345M
Eli Lilly And LLY:US USD 5.36B 305M
Gilead Sciences GILD:US USD 5.65B 829M
Horizon Pharma HZNP:US USD 691.23M 45.03M
Intra Cellular Therapies ITCI:US USD 66.02M 15.09M
IONIS PHARMACEUT IONS:US USD 158.25M 29.21M
JAZZ PHA JAZZ:US USD 806.99M 1.68M
Johnson & Johnson JNJ:US USD 15.94B 56M
Marinus Pharmaceuticals MRNS:US USD 2.29M 502K
Merk MRK:US USD 11.52B 1.08B
Nektar Therapeutics NKTR:US USD 18.65M 2.18M
Neurocrine Biosciences NBIX:US USD 381.8M 8.4M
Otsuka Holdings 4578:JP JPY 299.08B 13.03B
Pfizer PFE:US USD 16.55B 2.52B
Regeneron Pharmaceuticals REGN:US USD 2.62B 58.3M
Revance Therapeutics RVNC:US USD 18.28M 566K
Teva Pharmaceutical Industries TEVA:US USD 1.71B 118M
Vertex Pharmaceuticals VRTX:US USD 2.04B 110.5M